By Stephen NakrosisBristol Myers Squibb Co. on Friday said the U.S. Food and Drug Administration approved a pair of Opdivo-based regimens to treat certain cancer patients. Opdivo, or nivolumab, was approved in combination with chemotherapy, and Opdivo plus Yervoy also received approval to be first-line treatments for certain adult patients with esophageal squamous cell carcinoma. The approvals were based on a Phase 3 trial showing improved overall survival versus chemotherapy alone, Bristol Myers Squibb said. Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers, the company said. Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

Source: Wall Street Journal May 28, 2022 10:30 UTC